The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to negotiate a sole-source contract with Sofie Co. for the procurement of Piflufolastat F-18 injection drugs (Pylarify) essential for clinical nuclear medicine procedures at the NIH Clinical Center. The requirement includes 50 patient-ready unit doses of Piflufolastat F-18 and associated fees for unused doses, as these radiopharmaceuticals are critical for diagnosing and treating diseases in patients, adhering to strict FDA and NRC regulations. The contract period is set from March 14, 2025, to March 13, 2026, and interested parties may submit capability statements to Lu Chang at lu-chang.lu@nih.gov by 11:00 AM EST on March 14, 2025, for consideration.